Evaluation of biocompatible cardiopulmonary bypass circuit use during pediatric open heart surgery

Journal of Extra-Corporeal Technology

Volumn 38, Issue 1, 2006, Pages 22-26

  Deptula, Joseph ^a   Glogowski, Kimberly ^a   Merrigan, Kellie ^a   Hanson, Kim ^a   Felix, Donald ^a   Hammel, James ^a   Duncan, Kim ^a  

^a Children's Hospital Omaha   (United States)

Author keywords

2 methoxyethylacrylate; Biocompatible circuits; Congenital heart surgery; Immune response; Pediatric cardiopulmonary bypass

Indexed keywords

ACRYLIC ACID DERIVATIVE; POLY(2 METHOXYETHYLACRYLIC ACID); UNCLASSIFIED DRUG; BIOMATERIAL; POLY(2 METHOXYETHYLACRYLATE); POLY(2-METHOXYETHYLACRYLATE); POLYMER;

ARTICLE; BIOCOMPATIBILITY; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CHILD; CLINICAL EVALUATION; CONGENITAL HEART DISEASE; CONTROLLED STUDY; HUMAN; INTENSIVE CARE; MATERIAL COATING; OPEN HEART SURGERY; OXYGENATOR; PARAMETER; PEDIATRIC SURGERY; POSTOPERATIVE CARE; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TEST; CASE CONTROL STUDY; COMPLEMENT ACTIVATION; DRUG EFFECT; EVALUATION; EXTRACORPOREAL OXYGENATION; HEART SURGERY; INSTRUMENTATION; METHODOLOGY; PARTIAL THROMBOPLASTIN TIME; RETROSPECTIVE STUDY; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT;

ACRYLATES; BLOOD COAGULATION TESTS; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; CASE-CONTROL STUDIES; CHILD; COATED MATERIALS, BIOCOMPATIBLE; COMPLEMENT ACTIVATION; EXTRACORPOREAL MEMBRANE OXYGENATION; HUMANS; PARTIAL THROMBOPLASTIN TIME; PLATELET AGGREGATION; PLATELET COUNT; PLATELET FUNCTION TESTS; POLYMERS; RETROSPECTIVE STUDIES;

EID: 33744980219     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Chenoweth DE, Cooper SW, Hugh TE, Stewart RW, Blackstone EH, Kirklin JW. Complement activation during cardiopulmonary bypass. N Eng J Med. 1981;304:497-503.
2. Svennevig JL, Geiran OR, Karsen H, et al. Complement activation during extracorporeal circulation. In vitro comparison of Duraflo II heparin-coated and uncoated oxygenator. J Thorac Cardiovasc Surg. 1993;106:466-72.
3. Edmunds LH. Blood-surface interactions during cardiopulmonary bypass. J Card Surg. 1993;8:404-10.
4. Allen SM. Leukocyte depletion in cardiothoracic surgery. Perfusion. 1996;11:270-7.
5. Hill GE, Pohorecki R, Alonso A, Rennard SI, Robbins RA. Aprotinin reduces interleukin-8 production and lung neutrophil accumulation after cardiopulmonary bypass. Anesth Analg. 1996;83:696-700.
6. Hill GE, Alonso A, Spurzem RJR, Stammers AH, Robbins RA. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg. 1995;110:1658-62.
7. Takaori M, Fukui A, Kimura K, et al. Hemostatic mechanism associated with aprotinin during and after extracorporeal circulation for cardiac and great vessel surgery. Masui. 1995;44:1661-6.
8. Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood. 1990;76:1680-7.
9. Mannucci L, Gerometta PS, Mussoni L, et al. One month follow-up of haemostatic variables in patients undergoing aortocoronary bypass surgery. Effect of aprotinin. Thromb Haemost. 1995;73:356-61.
10. Stammers AH, Rasmussen CA, Kratz JM. Hemorrhagic effects of post cardiopulmonary bypass fibrinolysis. J Extra Corpor Technol. 1993;25:133-9.
11. Cameron D. Initiation of white cell activation during cardiopulmonary bypass: Cytokines and receptors. J Cardiovasc Pharmacol. 1996;27(suppl 1):S1-5.
12. Suhara H, Sawa Y, Nishimura M, et al. Efficacy of a new coating material, PMEA, for cardiopulmonary bypass circuits in a porcine model. Ann Thorac Surg. 2001;71:1602-8.
13. de Vroege R, van Oeveren W, van Klarenbosch J, et al. The impact of heparin-coated cardiopulmonary bypass circuits on pulmonary function and the release of inflammatory mediators. Anesth Analg. 2004;98:1586-94.
14. Zhang K, Hu Z, Yang Y, Huang R, Fan H, Sun Z. Protective effect of heparin-coated circuits on the platelets during cardiopulmonary bypass. J Huazhong Univ Sci Technolog Med Sci. 2003;23:403-6.
15. Kazaz H, Oto O, Sariosmanoglu N, Hazan E. The effects of heparin coated circuits on pulmonary injury. A clinical study. J Cardiovasc Surg (Torino). 2003;44:611-5.
16. Ikuta T, Fujii H, Shibata T, et al. A new poly-2-methoxyethylacrylate- coated cardiopulmonary bypass circuit possesses superior platelet preservation and inflammatory suppression efficacy. Ann Thorac Surg. 2004;77:1678-83.
17. Gunaydin S, Farsak B, Kocakulak M, Sari T, Yorgancioglu C, Zorlutuna Y. Clinical performance and biocompatibility of poly (2-methoxyethylacrylate)- coated extracorporeal circuits. Ann Thorac Surg. 2002;74:819-24.
18. Noguchi M, Eishi K, Tada S, et al. Biocompatibility of poly2methoxyethylacrylate coating for cardiopulmonary bypass. Ann Thorac Cardiovasc Surg. 2003;9:22-8.
19. Ninomiya M, Miyaji K, Takamoto S. Influence of PMEA-coated bypass circuits on perioperative inflammatory response. Ann Thorac Surg. 2003;75:913-7.
20. Zimmermann AK, Aebert H, Reiz A, et al. Hemocompatibility of PMEA coated oxygenators used for extracorporeal circulation procedures. ASAIO J. 2004;50:193-9.